Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02936479 · ClinicalTrials.gov registry record · Phase 2
C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02936479 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 1 participants.
The verdict
NCT02936479, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is an open-label, single arm trial in which patient who have ongoing antibody mediated rejection of a kidney transplant deemed refractory to maximal medical therapy are given the complement inhibitor C1-INH (Berinert) in an effort to protect the graft from ongoing antibody mediated injury. A maximum of 5 patients will be enrolled.
Interventions
- DRUG C1-INH (Berinert)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-10 |
| Est. Completion | 2018-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02936479
The ClinicalTrials.gov registry entry for NCT02936479 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which C1-INH (Berinert) is the first listed.
NCT02936479 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02936479 about?
NCT02936479 is a clinical study titled "C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection". This is an open-label, single arm trial in which patient who have ongoing antibody mediated rejection of a kidney transplant deemed refractory to maximal medical therapy are given the complement inhibitor C1-INH (Berinert) in an effort to protect the graft from ongoing antibody mediated injury. A ma...
What is the current status of trial NCT02936479?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2016-10. Estimated completion is 2018-10-30.
What interventions are being tested in trial NCT02936479?
The interventions under investigation include: C1-INH (Berinert) (DRUG).
Who is sponsoring clinical trial NCT02936479?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.